MiMedx Group (NASDAQ:MDXG) Shares Up 7.8% – What’s Next?

MiMedx Group, Inc (NASDAQ:MDXG)’s stock price was up 7.8% during mid-day trading on Monday . The stock traded as high as $4.44 and last traded at $4.4510. 173,992 shares were traded during mid-day trading, a decline of 87% from the average session volume of 1,315,922 shares. The stock had previously closed at $4.13.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on MDXG shares. Citizens Jmp lowered their price target on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a report on Thursday, April 30th. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 18th. Wall Street Zen cut shares of MiMedx Group from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Craig Hallum dropped their price target on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.50.

MiMedx Group Price Performance

The stock has a market capitalization of $622.40 million, a P/E ratio of 106.78 and a beta of 1.45. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The stock’s fifty day moving average is $3.95 and its two-hundred day moving average is $4.21.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The company had revenue of $64.36 million for the quarter, compared to analysts’ expectations of $63.46 million. As a group, research analysts predict that MiMedx Group, Inc will post -0.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MiMedx Group

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Williams & Novak LLC acquired a new position in shares of MiMedx Group in the 2nd quarter valued at $53,000. Bank of America Corp DE raised its holdings in MiMedx Group by 18.3% during the 1st quarter. Bank of America Corp DE now owns 572,295 shares of the company’s stock worth $2,261,000 after buying an additional 88,627 shares during the period. Sunbelt Securities Inc. acquired a new stake in MiMedx Group during the 1st quarter worth about $42,000. Punch & Associates Investment Management Inc. lifted its stake in MiMedx Group by 0.6% during the first quarter. Punch & Associates Investment Management Inc. now owns 2,019,718 shares of the company’s stock valued at $7,978,000 after buying an additional 12,524 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in MiMedx Group by 22.4% during the first quarter. Renaissance Technologies LLC now owns 3,019,871 shares of the company’s stock valued at $11,928,000 after buying an additional 552,806 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.